Review
Nature Reviews Drug Discovery 6, 29-40 (January 2007) | doi:10.1038/nrd2201
There is a Correspondence (November Issue 2007) associated with this article.
Focus on: Antibacterials
Drugs for bad bugs: confronting the challenges of antibacterial discovery
David J. Payne1, Michael N. Gwynn1, David J. Holmes1 & David L. Pompliano1 About the authors
Abstract
The sequencing of the first complete bacterial genome in 1995 heralded a new era of hope for antibacterial drug discoverers, who now had the tools to search entire genomes for new antibacterial targets. Several companies, including GlaxoSmithKline, moved back into the antibacterials area and embraced a genomics-derived, target-based approach to screen for new classes of drugs with novel modes of action. Here, we share our experience of evaluating more than 300 genes and 70 high-throughput screening campaigns over a period of 7 years, and look at what we learned and how that has influenced GlaxoSmithKline's antibacterials strategy going forward.
- View At a Glance
Author affiliations
- Infectious Diseases Centre of Excellence for Drug Discovery, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA.
Correspondence to: David L. Pompliano1 Email: David.L.Pompliano@gsk.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Genome sequencing Panspermia, spores and the Bacillus subtilisgenomeNature News and Views (20 Nov 1997)
Phage antibacterials make a comebackNature Biotechnology Research News (01 Aug 2001)
See all 3 matches for News And ViewsRESEARCH
Platensimycin is a selective FabF inhibitor with potent antibiotic propertiesNature Letters to Editor (18 May 2006)
See all 28 matches for Research